A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients with CKD Stage 3b and 4 (BalanceD-CKD)

Inclusion Criteria

• Inclusion Criteria:
• - Age ≥ 18 years
• - Diagnosis of CKD and at least one of the following:
• a. eGFR ≥ 15 to < 45 mL/min/1.73 m2 AND:
• UACR ≥ 30 mg/g (central laboratory) or
• UACR ≥ 100 mg/g (local laboratory ) or
• UPCR ≥ 200 mg/g (local laboratory).
• b. eGFR ≥ 15 to < 30 mL/min/1.73 m2 and UACR < 30 mg/g (local or
• central laboratory UACR value).
• - Serum/plasma K+ ≤ 5.0 mmol/L
• - Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening.
• Exclusion Criteria:
• - Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation
• - UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening.
• - SBP > 180 mmHg or DBP > 110 mmHg at screening.
• - SBP < 90 mmHg at screening.
• - HbA1c > 9% at screening
• - T1DM, except:
• a. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible.
• b. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion.
• - Autosomal dominant polycystic kidney disease.
• - Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening.
• - Severe hepatic impairment (Child-Pugh Class C).
• - Adrenal insufficiency.
• - Clinically significant acute kidney injury within 12 weeks prior to the screening.
• - New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening.
• - Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening.
• - Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation.
• - Any use of the following medications and supplements:
• a) MRAs
• b) Aldosterone analogues
• c) Aldosterone synthase inhibitors
• d) Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation.
• e) Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one
• week prior to randomisation